Sandberg Ake Andrén, Borgström Anders
JOP. 2002 Sep;3(5):116-25.
One out of ten cases of acute pancreatitis develops into severe acute pancreatitis which is a life threatening disorder with a high mortality rate. The other nine cases are self limiting and need very little therapy. The specificity of good clinical judgement on admission, concerning the prognosis of the attack, is high (high specificity) but misses a lot of severe cases (low sensitivity). The prediction of severity in acute pancreatitis was first suggested by John HC Ranson in 1974. Much effort has been put into finding a simple scoring system or a good biochemical marker for selecting the severe cases of acute pancreatitis immediately on admission. Today C-reactive protein is the method of choice although this marker is not valid until 48-72 hours after the onset of pain. Inflammatory mediators upstream from CRP like interleukin-6 and other cytokines are likely to react faster and preliminary results for some of these mediators look promising. Another successful approach has been to study markers for the activation of trypsinogen such as TAP and CAPAP. This is based on studies showing that active trypsin is the initial motor of the inflammatory process in acute pancreatitis. In the near future a combined clinical and laboratory approach for early severity prediction will be the most reliable. Clinical judgement predicts 1/3 of the severe cases on admission and early markers for either inflammation or trypsinogen activation should accurately identify 50-60% of the mild cases among the rest, thus missing only 2-4% of the remaining severe cases. One problem is that there is no simple and fast method to analyze any of these parameters.
每十例急性胰腺炎病例中就有一例发展为重症急性胰腺炎,这是一种危及生命的疾病,死亡率很高。其他九例为自限性,只需极少治疗。入院时对发作预后进行良好临床判断的特异性很高(高特异性),但会漏诊许多重症病例(低敏感性)。1974年,约翰·H·C·兰森首次提出对急性胰腺炎严重程度进行预测。人们付出了很多努力来寻找一种简单的评分系统或良好的生化标志物,以便在入院时立即筛选出急性胰腺炎的重症病例。如今,C反应蛋白是首选方法,尽管该标志物在疼痛发作后48 - 72小时才有效。像白细胞介素 - 6等在C反应蛋白上游的炎症介质可能反应更快,其中一些介质的初步结果看起来很有前景。另一种成功的方法是研究胰蛋白酶原激活的标志物,如TAP和CAPAP。这是基于研究表明活性胰蛋白酶是急性胰腺炎炎症过程的初始驱动因素。在不久的将来,结合临床和实验室的早期严重程度预测方法将是最可靠的。临床判断在入院时能预测三分之一的重症病例,早期炎症或胰蛋白酶原激活标志物应能准确识别其余病例中50 - 60%的轻症病例,从而仅漏诊其余重症病例的2 - 4%。一个问题是,没有简单快速的方法来分析这些参数中的任何一个。